Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCS

European Journal of Haematology

Volumn 43, Issue 1, 1989, Pages 54-62

  Osterborg A ^a   Ahre, A ^b   Bjorkholm M ^a   Bjoreman M ^e   Brenning, G ^d   Gahrton, G ^a   Gyllenhammar, H ^c   Johansson, B ^a   Juliusson, G ^a   Jarnmark M ^e   Killander, A ^d   Kimby, E ^b   Lerner, R ^c   Nilsson, B ^a   Paul, C ^a   Simonsson, B ^d   Stalfelt, A M ^e   Strander, H ^a   Smedmyr, B ^d   Svedmyr, E ^a   Uden A M ^c   Wadman, B ^e   Wedelin, C ^a   Mellstedt, H ^a   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

melphalan; multiple myeloma; prednisone; VMCP VBAP

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; CANCER CHEMOTHERAPY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; PROSPECTIVE STUDIES; RANDOM ALLOCATION; SWEDEN; VINCRISTINE;

EID: 0024348422     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1989.tb01252.x     Document Type: Article

References (32)

1. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimes
2. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M‐2 protocol
3. Evaluation of intensive (VBMCP) vs standard (MP) therapy for multiple myeloma (meeting abstract)
4. Improved survival of increased‐risk myeloma patients on combined triple‐alkylating‐agent therapy: at study of the CALGB
5. Treatment of multiple myeloma with an intensive 5‐drug combination or intermittent melphalan and prednisone: A randomized multicentre trial
6. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: A Southwest Oncology Group Study
7. High doses of natural α‐interferon (α‐IFN) in treatment of multiple myeloma — A pilot study from the Myeloma Group of Central Sweden (MGCS)
8. Intermittent melphalan and prednisolone therapy in plasma cell myeloma
9. A single radial diffusion method for the immunological quantification of protein
10. Electroimmunoassay
11. Determination of protein in urine by the Biuret method
12. A clinical staging system for multiple myeloma
13. National Cancer Institute. Proposed guide lines for protocol studies. II. Plasmacell myeloma
14. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
15. The survival time of patients with plasmacytic myeloma
16. Melphalan and myeloma. Experience with a low‐dose continuous regimen
17. Report on the second myelomatosis trial after five years of follow up
18. Treatment comparisons in the third MRC myelomatosis trial
19. Prednisone pulse therapy for refractory myeloma
20. Response rate and survival in myeloma patients receiving prednisone alone
21. Phase III study of intermittent 5‐drug regimen (VBMCP) versus intermittent 3‐drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis
22. Multiple myeloma in central Norway 1981–1982: A randomized clinical trial of 5‐drug combination therapy versus standard therapy
23. The chemotherapy of plasma‐cell myeloma and the incidence of acute leukemia
24. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three‐ and five‐drug combinations: An argentine group for the treatment of acute leukemia study
25. Single, sequential and multiple alkylating agent therapy for multiple myeloma: A CALGB study
26. Improved survival duration with combination chemotherapy induction for multiple myeloma: A South‐West Oncology Group Study
27. Chemotherapy for multiple myeloma
28. Results of the MRC myelomatosis trials for patients entered since 1980